Zelf verwacht ik dat Jeito Capital (nog steeds) aan het kopen is.
Nog even de redenen op een rijtje:
-PARIS, Jan. 15, 2020 /PRNewswire/ -- Rafaèle Tordjman launches JEITO CAPITAL,
a new French and independent investment investor dedicated to biotech and
biopharma. The launch is completed by the closing of JEITO I fund's with the
support and investment of renowned institutional investors and family offices
totaling €200 million to date.
-Our goal is to support start-ups' growth destined to become the
market leaders of tomorrow.
Rafaèle Tordjman is also keen to promote impact investment via the JEITO
Foundation and to support the international network W.I.T.H (Women Innovating
Together in Healthcare).
AWARDED WOMAN OF THE YEAR BY W.I.T.H
2018 : Fiona Marshall, VP Head of Discovery Research - MSD
2017 : Mary Lynne Hedley, President, COO, cofounder - TESARO
2016 : Bahija Jallal, Executive VP - AstraZeneca / Head - MedImmune
2015 : Karen Aiach, Founder & CEO - Lysogene
2014 : Maria-Gabriella Camboni, Founder & COO - EOS
2013 : Alice Dautry, President - Pasteur Institute
Rafaèle Tordjman, MD PhD, has been an investor in life sciences since 2001.
She joined Sofinnova Partners in 2001, a Paris-based venture capital firm, as
an analyst. She became co-leader and partner with €1.5 billion of assets under
management, which she held until 2017.
Among other companies, Rafaèle invested in and served on the boards of DBV
Technologies [DBV], Ascendis [ASND], Lysogene [LYS], MedDay, Enyo Pharma,
Nucana Biomed [NCNA], ObsEva [OBSV], Flexion Therapeutics [FLXN] and Preglem,
before the company was sold to Gedeon Richter.
Misschien aan het eind van de dag een melding, maar ander nieuws dat de enorme stijging en omzet van afgelopen week verklaart, mag natuurlijk ook.